Latest Erlotinib Stories
Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex,
-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR
MIT researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage.
The Majority of Non-Prescribers Anticipate Prescribing Gilotrif Within the Next Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., April 24, 2014 /PRNewswire/
Researchers have located a biomarker that they believe could help explain why many of the medications used to treat lung, breast and pancreatic cancers also promote drug resistance and ultimately cause tumors to form in patients.
Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival.
New data demonstrates VAL-083 is superior to standard platinum-based chemotherapy in an established in vivo model of non-small cell lung cancer (NSCLC) VANCOUVER, British Columbia, MENLO PARK,
A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system.
A team of Brazilian scientists has identified a promising new combination treatment that targets cervical cancer, according to a new report published in the journal Cancer.
Highlights BGB324's potential as a novel treatment for NSCLC in patients with acquired drug resistance BERGEN, Norway, January 9, 2014 /PRNewswire/ -- Highlights
- The practice of two or more parties jointly purchasing all or part of a butchered cow and dividing the meat between them.